Mediwound Ltd (NASDAQ:MDWD) Sees Significant Decline in Short Interest

Share on StockTwits

Mediwound Ltd (NASDAQ:MDWD) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 173,100 shares, a drop of 5.2% from the May 30th total of 182,600 shares. Based on an average trading volume of 81,700 shares, the short-interest ratio is currently 2.1 days. Currently, 1.1% of the company’s shares are sold short.

A number of hedge funds have recently made changes to their positions in MDWD. Delek Group Ltd. bought a new position in shares of Mediwound during the 1st quarter worth approximately $141,000. Meitav Dash Investments Ltd. grew its stake in shares of Mediwound by 0.6% during the 1st quarter. Meitav Dash Investments Ltd. now owns 598,508 shares of the biopharmaceutical company’s stock worth $2,993,000 after acquiring an additional 3,536 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Mediwound by 73.5% during the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock worth $161,000 after acquiring an additional 16,840 shares in the last quarter. Menta Capital LLC grew its stake in shares of Mediwound by 200.2% during the 1st quarter. Menta Capital LLC now owns 44,514 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 29,686 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Mediwound by 33.2% during the 4th quarter. Millennium Management LLC now owns 68,365 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 17,048 shares in the last quarter. Hedge funds and other institutional investors own 30.78% of the company’s stock.

A number of brokerages recently weighed in on MDWD. ValuEngine downgraded shares of Virtu Financial from a “hold” rating to a “sell” rating in a research report on Tuesday, June 18th. Zacks Investment Research downgraded shares of Farmland Partners from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Oppenheimer set a $22.00 target price on shares of Par Pacific and gave the stock a “buy” rating in a report on Monday, March 25th.

MDWD stock remained flat at $$3.11 during mid-day trading on Tuesday. 857 shares of the company’s stock traded hands, compared to its average volume of 60,551. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.79 and a current ratio of 3.99. The firm has a market cap of $84.53 million, a P/E ratio of -6.35 and a beta of 0.58. The firm’s fifty day moving average is $3.62. Mediwound has a 52-week low of $3.00 and a 52-week high of $6.75.

Mediwound (NASDAQ:MDWD) last announced its earnings results on Tuesday, May 21st. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.60 million. Mediwound had a negative return on equity of 383.19% and a negative net margin of 18.43%. On average, analysts predict that Mediwound will post -0.59 earnings per share for the current fiscal year.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Story: How to read a candlestick chart

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Avaya  Earns “Buy” Rating from Northland Securities
Avaya Earns “Buy” Rating from Northland Securities
Bloom Energy  Earns Overweight Rating from KeyCorp
Bloom Energy Earns Overweight Rating from KeyCorp
Bristol-Myers Squibb  Lifted to “Overweight” at Atlantic Securities
Bristol-Myers Squibb Lifted to “Overweight” at Atlantic Securities
Argus Boosts AstraZeneca  Price Target to $50.00
Argus Boosts AstraZeneca Price Target to $50.00
JPMorgan Chase & Co. Raises Agnico Eagle Mines  Price Target to $83.00
JPMorgan Chase & Co. Raises Agnico Eagle Mines Price Target to $83.00
Deutsche Bank Reaffirms “Buy” Rating for Ashford Hospitality Trust
Deutsche Bank Reaffirms “Buy” Rating for Ashford Hospitality Trust


© 2006-2019 Ticker Report